Apr 18, 2026
The largest CAR-T trial for pediatric solid tumors has opened in the US and UK, enrolling up to 60 young patients across four sites. The NexTGen study targets relapsed or refractory cancers and focuses first on safety and feasibility.
Mar 24, 2026
Dana-Farber Cancer Institute will host the Fifth Transatlantic Exchange in Oncology on March 27, 2026, featuring discussions on epigenetic therapies, microbiome-driven immunity, and cellular pathway reprogramming. The event continues collaboration between Dana-Farber and France's Gustave Roussy cancer center with support from L'Institut Servier and Medscape Medical Affairs.
Mar 11, 2026
Researchers have created a nasal vaccine platform that protects mice against flu, COVID-19, SARS, and bacterial infections by activating both innate and adaptive immune systems, offering a fundamentally different approach to disease prevention.
Mar 10, 2026
Recent publications and collaborations advance glioblastoma research through blood-based microRNA diagnostics, combination immunotherapy trials, and identification of MOV10 as a prognostic biomarker and therapeutic target.
Mar 02, 2026
A CNIC study demonstrates that remote ischemic conditioning can protect the heart during anthracycline chemotherapy without compromising antitumor efficacy, while researchers explore additional methods to manage chemotherapy side effects.